These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 8395736)

  • 1. Anti-factor Xa determination in blood: a new method for controlling heparin therapy.
    Harenberg J; Haaf B; Schäfer M; Dempfle CE; Stehle G; Heene DL
    Semin Thromb Hemost; 1993; 19 Suppl 1():79-85. PubMed ID: 8395736
    [No Abstract]   [Full Text] [Related]  

  • 2. Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay.
    Harenberg J; Haaf B; Dempfle CE; Stehle G; Heene DL
    Nephrol Dial Transplant; 1995; 10(2):217-22. PubMed ID: 7753456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparative study of low molecular weight heparin and unfractionated heparin in patients on maintenance hemodialysis].
    Noguchi M; Izumi K; Deguchi K; Endoh T; Tsuda M; Shirakawa S
    Rinsho Byori; 1990 Jul; Suppl 86():177-83. PubMed ID: 2172594
    [No Abstract]   [Full Text] [Related]  

  • 4. Heparin and low molecular weight heparin: is anti-factor Xa activity important?
    Lane DA; Ryan K
    J Lab Clin Med; 1989 Oct; 114(4):331-3. PubMed ID: 2551984
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of anticoagulation efficacy and clinical safety between imported and domestically manufactured low-molecular-weight heparin during hemodialysis.
    Liu ZQ; Wang L
    Di Yi Jun Yi Da Xue Xue Bao; 2002 Oct; 22(10):942-3. PubMed ID: 12377628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new chronometric assay to determine plasma antifactor Xa activity which is insensitive to the antithrombin activity of low molecular weight heparins.
    Dignac M; Gabaig AM; Cambus JP; Boneu B
    Nouv Rev Fr Hematol (1978); 1994; 35(6):545-9. PubMed ID: 8152901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability.
    Kitchen S; Iampietro R; Woolley AM; Preston FE
    Thromb Haemost; 1999 Oct; 82(4):1289-93. PubMed ID: 10544915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute effect of standard heparin versus low molecular weight heparin on oxidative stress and inflammation in hemodialysis patients.
    Poyrazoglu OK; Dogukan A; Yalniz M; Seckin D; Gunal AL
    Ren Fail; 2006; 28(8):723-7. PubMed ID: 17162433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Equivalent effective doses of heparin and low molecular weight heparin(oid)s in haemodialysis for chronic renal failure.
    Lane DA; Ireland H; Tew CJ; Flynn A; Curtis JR
    Acta Chir Scand Suppl; 1988; 543():101-4. PubMed ID: 2847457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of low molecular weight heparin as an anti-coagulant for hemodialysis].
    Akizawa T; Kanamori N; Koshikawa S
    Rinsho Byori; 1990 Jul; Suppl 86():171-6. PubMed ID: 2172593
    [No Abstract]   [Full Text] [Related]  

  • 11. A single dose of a low molecular weight heparin fragment for anticoagulation during hemodialysis.
    Ljungberg B; Blombäck M; Johnsson H; Lins LE
    Clin Nephrol; 1987 Jan; 27(1):31-5. PubMed ID: 3815906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale for the use of a low molecular weight heparin during hemodialysis with polysulphone membrane in uremic patients.
    Moia M; Graziani G; Tenconi PM; Martinelli I; Ponticelli C
    Ann Ital Med Int; 1997; 12(2):67-71. PubMed ID: 9284597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics of unfractionated heparin during and after a hemodialysis session.
    Brunet P; Simon N; Opris A; Faure V; Lorec-Penet AM; Portugal H; Dussol B; Berland Y
    Am J Kidney Dis; 2008 May; 51(5):789-95. PubMed ID: 18436089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulant-free Genius haemodialysis using low molecular weight heparin-coated circuits.
    Frank RD; Müller U; Lanzmich R; Groeger C; Floege J
    Nephrol Dial Transplant; 2006 Apr; 21(4):1013-8. PubMed ID: 16326745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of intimal hyperplasia with low molecular weight heparin in a sheep model.
    Ao PY; Hawthorne WJ; Coombs R; Fletcher JP
    Int Angiol; 1999 Jun; 18(2):131-9. PubMed ID: 10424369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin.
    Kovacs MJ; Keeney M; MacKinnon K; Boyle E
    Clin Lab Haematol; 1999 Feb; 21(1):55-60. PubMed ID: 10197265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Use of low-molecular weight heparin during hemodialysis].
    Kalinowski M; Pawlak K; Myśliwiec M; Popławski A
    Pol Merkur Lekarski; 1997 Jan; 2(9):208-10. PubMed ID: 10907031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies.
    Brophy DF; Carr ME; Martin EJ; Venitz J; Gehr TW
    J Clin Pharmacol; 2006 Aug; 46(8):887-94. PubMed ID: 16855073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravascular release and urinary excretion of tissue factor pathway inhibitor during heparin treatment.
    Brodin E; Svensson B; Paulssen RH; Nordoy A; Hansen JB
    J Lab Clin Med; 2004 Nov; 144(5):246-53; discussion 226-7. PubMed ID: 15570242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The activity of heparin in the presence and absence of Ca2+ ions; why the anti-Xa activity of LMW heparins is about two times overestimated.
    Hemker HC; Béguin S
    Thromb Haemost; 1993 Oct; 70(4):717-8. PubMed ID: 8116003
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.